

# Osimertinib improves symptoms in advanced lung cancer patients

May 5 2017

---

Osimertinib improves cancer-related symptoms in patients with advanced lung cancer, according to an analysis of patient-reported outcomes from the AURA3 phase III clinical trial presented at the European Lung Cancer Conference (ELCC).<sup>1</sup>

"With my past experience conducting clinical trials, I often see new treatments that might be more effective, but are also usually more toxic," said lead author Dr Chee Lee, Medical Oncologist, St George Hospital Cancer Care Centre, New South Wales, Australia. "Osimertinib not only increases progression-free survival but it is well-tolerated, which makes a big difference for our patients."

AURA3 included 419 patients with advanced epidermal growth factor receptor (EGFR) mutation non-small-cell [lung cancer](#) (NSCLC) who had progressed after first-line EGFR-tyrosine kinase inhibitor (TKI) therapy. They were randomised to receive the oral TKI osimertinib or chemotherapy. Patients taking osimertinib had significantly longer progression-free survival of 10.1 months versus those on chemotherapy with 4.4 months (hazard ratio 0.30; 95% confidence interval 0.23, 0.41; p

Citation: Osimertinib improves symptoms in advanced lung cancer patients (2017, May 5) retrieved 2 May 2024 from <https://medicalxpress.com/news/2017-05-osimertinib-symptoms-advanced-lung-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.